$240.13+0.81%Close 17 Nov 2026 · Market value $33.61B
About ResMed|
ResMed is a digital health and cloud-connected medical device company that designs CPAP, bilevel, ventilation and high flow therapy devices, masks and accessories, diagnostic products, and cloud-based software for the treatment of sleep and breathing disorders. Its products are used predominantly in the home and to a lesser extent in hospitals, and it sells them through wholly owned subsidiaries and independent distributors in more than 140 countries. ResMed operates two segments: Sleep and Breathing Health and Residential Care Software. The Residential Care Software business provides cloud-based solutions to home medical equipment providers, home health and hospice providers, skilled nursing facilities, senior living communities and related residential care providers in the U.S. and Germany, among others. The company employs approximately 11,370 people.
A summary of the business section of the company's latest annual report, filed 13 Aug 2026.
Company facts
| Ticker | RMD · NYSE |
|---|
| Sector | Medical devices |
|---|
| Industry | Health Care Equipment |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 30 June |
|---|
| Reporting currency | USD |
|---|
| CIK | 943819 |
|---|
| Latest annual report | 10-K, filed 13 Aug 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Michael Farrell | Chairman and CEO · Director | 604K · < 1% | Shares withheld for tax, 11 Nov 2026 |
|---|
| Brett Sandercock | Chief Financial Officer | 57.0K · < 1% | Sale under a 10b5-1 plan, 1 Apr 2026 |
|---|
| Peter Farrell | Director | 56.3K · < 1% | Shares withheld for tax, 11 Nov 2026 |
|---|
| Justin Leong | Chief Product Officer | 51.7K · < 1% | Grant or award, 14 Aug 2026 |
|---|
| Ronald Taylor | Director | 24.8K · < 1% | Grant or award, 20 Nov 2025 |
|---|
| Karen Drexler | Director | 21.1K · < 1% | Grant or award, 20 Nov 2025 |
|---|
| Carol Burt | Director | 18.8K · < 1% | Grant or award, 20 Nov 2025 |
|---|
| Harjit Gill | Director | 10.9K · < 1% | Shares withheld for tax, 11 Nov 2026 |
|---|
| Michael Rider | Global General Counsel | 9.6K · < 1% | Shares withheld for tax, 11 Nov 2026 |
|---|
| Desney Tan | Director | 6.0K · < 1% | Grant or award, 20 Nov 2025 |
|---|
| John Hernandez | Director | 5.1K · < 1% | Grant or award, 20 Nov 2025 |
|---|
| Jan De Witte | Director | 4.3K · < 1% | Shares withheld for tax, 11 Nov 2026 |
|---|
| Christopher DelOrefice | Director | 2.4K · < 1% | Grant or award, 20 Nov 2025 |
|---|
| Nicole Mowad-Nassar | Director | 2.1K · < 1% | Grant or award, 20 Nov 2025 |
|---|
| Aaron Bloomer | Chief Financial Officer | — | Shares withheld for tax, 11 Nov 2026 |
|---|
| Ghoshal Kaushik | Chief Commercial Officer, SaaS | — | Option exercise, 10 Mar 2025 |
|---|
| SULPIZIO RICHARD | Director | — | Grant or award, 20 Nov 2024 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
RMD in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.